Phathom Pharmaceuticals Inc Ordinary shares PHAT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026
-
Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026
-
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
-
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
-
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
-
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
-
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)
-
PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals
Trading Information
- Previous Close Price
- $7.31
- Day Range
- $7.01–7.48
- 52-Week Range
- $6.52–18.31
- Bid/Ask
- $6.60 / $7.30
- Shares Outstanding
- 80.90M
- Market Cap
- $568.73M
- Volume/Avg
- 7 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.30
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 371
- Website
- https://www.phathompharma.com
Valuation
|
Metric
|
PHAT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 2.30 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PHAT
|
|---|---|
Quick Ratio | 1.82 |
Current Ratio | 1.92 |
Interest Coverage | −0.65 |
Quick Ratio
PHAT
Profitability
|
Metric
|
PHAT
|
|---|---|
Return on Assets (Normalized) | −11.47% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
PHAT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@Zf^q< | LOCK|Cd%s< | $133B | |||
| Moderna Inc
MRNA
| LOCK|V!zCkT | LOCK|W!k | $98B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|j?<@^$ | LOCK|!jr?# | $83B | |||
| argenx SE ADR
ARGX
| LOCK|MQ?pQb | LOCK|&vy | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|g&zk$r | LOCK|rG | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|##Y^&x | LOCK|xLnF$ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!Cy$k$P | LOCK|>HSv? | $28B | |||
| Incyte Corp
INCY
| LOCK|M@q&?m | LOCK|s$ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|%%rY?#G | LOCK|>@ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|b&wLN<t | LOCK|rK$ | $14B |
United States